120 related articles for article (PubMed ID: 10415871)
1. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Miknyoczki SJ; Dionne CA; Klein-Szanto AJ; Ruggeri BA
Ann N Y Acad Sci; 1999 Jun; 880():252-62. PubMed ID: 10415871
[TBL] [Abstract][Full Text] [Related]
2. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
[TBL] [Abstract][Full Text] [Related]
3. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
5. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior.
Miknyoczki SJ; Lang D; Huang L; Klein-Szanto AJ; Dionne CA; Ruggeri BA
Int J Cancer; 1999 May; 81(3):417-27. PubMed ID: 10209957
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Dionne CA; Camoratto AM; Jani JP; Emerson E; Neff N; Vaught JL; Murakata C; Djakiew D; Lamb J; Bova S; George D; Isaacs JT
Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
[TBL] [Abstract][Full Text] [Related]
7. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
8. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
Camoratto AM; Jani JP; Angeles TS; Maroney AC; Sanders CY; Murakata C; Neff NT; Vaught JL; Isaacs JT; Dionne CA
Int J Cancer; 1997 Aug; 72(4):673-9. PubMed ID: 9259409
[TBL] [Abstract][Full Text] [Related]
9. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Weeraratna AT; Dalrymple SL; Lamb JC; Denmeade SR; Miknyoczki S; Dionne CA; Isaacs JT
Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
11. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
Evans AE; Kisselbach KD; Liu X; Eggert A; Ikegaki N; Camoratto AM; Dionne C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):181-4. PubMed ID: 11464878
[TBL] [Abstract][Full Text] [Related]
12. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
13. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
[TBL] [Abstract][Full Text] [Related]
14. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
Pinski J; Weeraratna A; Uzgare AR; Arnold JT; Denmeade SR; Isaacs JT
Cancer Res; 2002 Feb; 62(4):986-9. PubMed ID: 11861369
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
Evans AE; Kisselbach KD; Yamashiro DJ; Ikegaki N; Camoratto AM; Dionne CA; Brodeur GM
Clin Cancer Res; 1999 Nov; 5(11):3594-602. PubMed ID: 10589776
[TBL] [Abstract][Full Text] [Related]
16. Mixed-lineage kinase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival.
Wang LH; Paden AJ; Johnson EM
J Pharmacol Exp Ther; 2005 Mar; 312(3):1007-19. PubMed ID: 15525794
[TBL] [Abstract][Full Text] [Related]
17. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
18. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
[TBL] [Abstract][Full Text] [Related]
19. Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma.
Sakamoto Y; Kitajima Y; Edakuni G; Sasatomi E; Mori M; Kitahara K; Miyazaki K
Oncol Rep; 2001; 8(3):477-84. PubMed ID: 11295066
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
